Growth funding BEKhealth recently secured a $5M financing round to support expansion, indicating an aggressive growth trajectory. This presents an opportunity to align with their scaling needs, such as enterprise-grade integrations, additional data sources, and expanded customer success resources.

Platform expansion The launches of BEKScore and SiteWorks in 2024 signal a push to broaden product capabilities and CRM-enabled workflow for research teams. Targeted upsell channels include advanced analytics, AI-driven trial design support, and deeper CRM integrations that streamline site recruitment.

EMR data advantage BEKhealth emphasizes extracting three times more trial criteria from EMRs for faster patient matching. Sales conversations can highlight value propositions around more efficient feasibility assessments, faster trial start timelines, and improved patient enrollment rates for sponsors and CROs.

Leadership momentum New executive leadership and strategic hires in 2024 reflect a focus on corporate strategy and clinical consultation tools. This suggests an openness to strategic partnerships, white-label opportunities, and collaborative go-to-market programs with larger trial networks.

Real-time insights Recent emphasis on real-time clinical insights and real-world evidence aligns BEKhealth with current market trends favoring data-driven trial operations. Opportunities exist to partner with pharma sponsors seeking rapid feasibility, adaptive trial design support, and robust data extraction workflows across EMR ecosystems.